Cancer Institute A national cancer institute
designated cancer center

George Triadafilopoulos

Publication Details

  • Indications and safety of proton pump inhibitor drug use in patients with cancer EXPERT OPINION ON DRUG SAFETY Triadafilopoulos, G., Roorda, A. K., Akiyama, J. 2013; 12 (5): 659-672


    Introduction: Although the exact prevalence of proton pump inhibitor (PPI) use in cancer patients is not known, it is generally perceived to be widespread. PPIs are generally well tolerated and carry an excellent safety profile. However, increasing and longer term PPI use has raised concerns about the risk of pneumonia, bone fractures and enteric infections, and a possible interaction with clopidogrel that could increase the risk of cardiovascular events. Areas covered: We conducted a PubMed search of English language articles addressing the safety and adverse events associated with PPI use with particular emphasis in cancer patients. Expert opinion: PPIs, frequently used in cancer patients, are generally well tolerated and carry an excellent safety profile. PPI-induced acid suppression may increase the risk of Clostridium difficile or other enteric infections, nutritional deficiencies and community acquired pneumonia, all particularly important in cancer patients. The indications for PPI use in cancer patients should be carefully reviewed prior to use.

    View details for DOI 10.1517/14740338.2013.797961

    View details for Web of Science ID 000323488900007

Stanford Medicine Resources:

Footer Links: